Menu
Back to Journals » OncoTargets and Therapy » Volume 12
RETRACTED ARTICLE: Upregulated miR-27a-3p Indicates a Poor Prognosis in Pancreatic Carcinoma Patients and Promotes the Angiogenesis and Migration by Epigenetic Silencing of GATA6 and Activating VEGFA/VEGFR2 Signaling Pathway
Authors Rao X, Wan L, Jie Z, Zhu X, Yin J, Cao H
Received 24 June 2019
Accepted for publication 16 November 2019
Published 19 December 2019 Volume 2019:12 Pages 11241—11254
DOI https://doi.org/10.2147/OTT.S220621
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Gaetano Romano
This paper has been retracted.
Rao X, Wan L, Jie Z, Zhu X, Yin J, Cao H. Onco Targets Ther. 2019;12:11241–11254.
We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.
Since publication, concerns have been raised about the integrity of the data in the article. When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.